The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Investigating the impact of frailty on outcomes of patients with AML
Aniket Bankar, MD, DM, MBBS, MSc, Princess Margaret Cancer Center, Toronto, Canada, discusses the results of a study assessing the impact of frailty on the outcomes of patients with acute myeloid leukemia (AML). Patients with higher frailty were found to have poor overall survival (OS), irrespective of age. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
